KING OF PRUSSIA, Pa.,
Feb. 27, 2015 /PRNewswire/ -- In
recognition of Rare Disease Day and as part of its ongoing
commitment to the global bleeding disorders community, CSL Behring
announced today that it is donating 2 million international units
(IUs) of protein therapies to the World Federation of Hemophilia
(WFH). WFH is an international not-for- profit organization
which has worked to improve the lives of people with hemophilia and
other inherited bleeding disorders. The donation supports the WFH's
Global Alliance for Progress (GAP) Program aimed at improving the
diagnosis and treatment of bleeding disorders in developing
countries. CSL was the first biotherapies company in the world to
make a multiyear commitment to WFH to aid the GAP Program with
coagulation factor donations over an extended period of time,
starting in 2009. Rare Disease Day, February
28, is coordinated by the European Organization for Rare
Diseases (EURORDIS) and by several national alliances and patient
organizations around the globe.
"We take great pride in the progress of the GAP Program and are
grateful for the generous donations made by CSL Behring," said WFH
President Alain Weill. "We look
forward to our continued partnership with CSL Behring as we
strive to help fulfill our commitment to introduce clotting factor
concentrates in developing countries where people who are living
with a bleeding disorder may not be able to access appropriate
treatment."
"CSL Behring is committed to improving the well-being of people
who are living with rare or serious diseases," said Paul Perreault, CEO and Managing Director of CSL
Limited. "The GAP Program has made excellent progress over the
years and continues to align with our goal to make meaningful
differences in the lives of people who are living with serious
diseases, such as hemophilia or von Willebrand disease."
In 2012, CSL Behring renewed its product donation contract with
WFH, for the period 2013 through 2015. Since 2012, CSL Behring has
donated close to 7.7 million IUs of its bleeding disorders
therapies to treat people with hemophilia or von Willebrand disease
(VWD) in developing countries.
About the Global Alliance for Progress
The Global Alliance for Progress (GAP) Program is a healthcare
development project launched in 2003, now entering the Second
Decade phase. GAP's goal is to greatly increase the diagnosis and
treatment of people with hemophilia and other bleeding disorders in
developing countries.
The program aims to close the gap between the number of people
born with hemophilia and those who reach adulthood, the gap between
the estimated and actual number of people diagnosed with bleeding
disorders, and the gap between the volume of treatment product
needed versus what is available. CSL Behring supports the WFH GAP
Program as one of the program sponsors.
About the World Federation of Hemophilia
For over 50 years, the World Federation of Hemophilia (WFH), an
international not-for- profit organization, has worked to improve
the lives of people with hemophilia and other inherited bleeding
disorders. Established in 1963, it is a global network of patient
organizations in 127 countries and has official recognition from
the World Health Organization. Visit WFH online at www.wfh.org
About CSL Behring
CSL Behring is a leader in
the plasma protein therapeutics industry. Committed to saving lives
and improving the quality of life for people with rare and serious
diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat
coagulation disorders including hemophilia and von Willebrand
disease, primary immune deficiencies, hereditary angioedema and
inherited respiratory disease, and neurological disorders in
certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent
hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma
collection networks, CSL Plasma. CSL Behring is a global
biopharmaceutical company and a member of the CSL Group of
companies. The parent company, CSL Limited (ASX:CSL), is
headquartered in Melbourne,
Australia. For more information, visit
http://www.cslbehring.com/.
Contact:
Sarah Ford
World Federation of Hemophilia
Office: 514-394-2822
sford@wfh.org
Greg Healy
CSL Behring Office: 610-878-4841
Mobile: 610-906-4564
Greg.Healy@CSLBehring.com
Logo -
http://photos.prnewswire.com/prnh/20100914/PH63692LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/csl-behring-continues-treatment-access-leadership-by-donating-bleeding-disorder-protein-therapies-ius-to-world-federation-of-hemophilia-300042763.html
SOURCE CSL Behring
